Stock Detail
TELIK INC
Diversified Services
TELK @ Yahoo Finance | TELK Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.25 | $0.25 | $0.02 | 8.70% | 0.00 | $0.23 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.24 | $0.23 | 16,700 | 13.49M | 51,332.5 | -0.69 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.26 | 0.25 | 0.24 | 0.23 | 0.22 |
Stock Profile
Telik, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs in the United States. Its primary product candidate, TELCYTA, is a small molecule tumor-activated cancer product candidate, which is being evaluated for the treatment of cancers that are resistant to standard chemotherapy drugs. The TELCYTA is in three Phase 3 registration trials for the treatment of advanced ovarian cancer, nonsmall cell lung cancer, and refractory ovarian cancer. The company's another product candidate, TELINTRA, is a small molecule bone marrow stimulant, which is being developed for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The TELINTRA is in Phase 2 trial in patients with myelodysplastic syndrome. Telik has collaboration agreements with Sanwa Kagaku Kenkyusho Co., Ltd. and Hoffmann-La Roche, Inc. The company was formed as Terrapin Diagnostics, Inc. in 1988 and changed its name to Terrapin Technologies, Inc. in 1989. Further, Terrapin Technologies changed its name to Telik, Inc. in 1998. Telik is based in Palo Alto, California.